Addex Therapeutics GABAB Positive Allosteric Modulator Program Receives Additional CHF2.7M From Indivior In Extended Substance Use Disorder Research Collaboration
Portfolio Pulse from Benzinga Newsdesk
Addex Therapeutics has received an additional CHF2.7M from Indivior for its GABAB Positive Allosteric Modulator Program. The funds are part of an extended research collaboration on substance use disorder.
August 04, 2023 | 12:35 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Addex Therapeutics has received additional funding from Indivior, which could boost its research capabilities and financial stability.
The additional funding from Indivior is a positive development for Addex Therapeutics. It not only provides financial support but also validates the company's research program. This could potentially lead to positive investor sentiment and an increase in the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100